ATOM vs Dna Which Performs Better?

ATOM and DNA stocks are two different investment options that are popular among investors. ATOM stocks are associated with companies that are focused on cutting-edge technology and innovation, while DNA stocks are linked to the biotechnology sector. Both types of stocks have the potential for significant growth and profitability, but they also come with their own set of risks. It is important for investors to carefully research and analyze these two options before making any investment decisions.

ATOM or Dna?

When comparing ATOM and Dna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between ATOM and Dna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. ATOM has a dividend yield of -%, while Dna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. ATOM reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Dna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with ATOM P/E ratio at -88.44 and Dna's P/E ratio at 6.61. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. ATOM P/B ratio is 22.24 while Dna's P/B ratio is 1.01.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, ATOM has seen a 5-year revenue growth of -0.32%, while Dna's is 0.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with ATOM's ROE at -22.11% and Dna's ROE at 16.96%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ¥683.00 for ATOM and ₪79.50 for Dna. Over the past year, ATOM's prices ranged from ¥634.00 to ¥944.00, with a yearly change of 48.90%. Dna's prices fluctuated between ₪56.00 and ₪105.00, with a yearly change of 87.50%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.